News
Positive Results: Pembrolizumab and Chemotherapy Combo Improves Pathological Complete Response in High-Risk ER+/HER2- Breast Cancer Patients
Oncologyme
/ Nov 03, 2023
Groundbreaking Breakthrough: Alectinib Revolutionizes Treatment for Completely Resected ALK-Positive NSCLC
Oncologyme
/ Oct 29, 2023
Enfortumab Vedotin and Pembrolizumab: Transforming First Line Treatment for Advanced Urothelial Cancer, a Landmark Breakthrough in Decades
Oncologyme
/ Oct 29, 2023
Dose-Dense MVAC Outperforms GC for MIBC: VESPER Trial Update Reveals Enhanced Overall and Disease-Specific Survival
Oncologyme
/ Oct 18, 2023
Comparison of Neoadjuvant Chemotherapy Plus Surgery and Concomitant Chemoradiotherapy in Stage IB2 to IIB Cervical Carcinoma: Insights from EORTC-55994 Trial
Oncologyme
/ Oct 17, 2023
Comparison of Neoadjuvant Chemotherapy Plus Surgery and Concomitant Chemoradiotherapy in Stage IB2 to IIB Cervical Carcinoma: Insights from EORTC-55994 Trial
Oncologyme
/ Oct 17, 2023
Promising Outcomes of Combined Therapy in Metastatic Castration-Sensitive Prostate Cancer: Findings from the PEACE-1 Trial
Oncologyme
/ Oct 17, 2023
.png)
Improving Clinical Outcomes in Refractory RAS Wild-Type MCRC: The Velo Trial Shows Promise with Panitumumab and Trifluridine-Tipiracil
Oncologyme
/ Oct 10, 2023
.png)